Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report

Diep, Calvin; Rosenek, Norma; Khoo, Yuelee; Gandhi, Wiebke; Reekum, Carien M. van; Ravindran, Arun; Ladha, Karim; Frey, Benício N.; Milev, Roumen; Rotzinger, Susan; Lam, Raymond W.; Kennedy, Sidney H.; Lou, Wendy; Salomons, Tim V.; Bhat, Venkat

doi:10.1016/j.psychres.2022.114557

Cited by 4 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the previous study was a secondary analysis that lacked randomization or comparison to placebo. 45 Regarding the hemodynamic parameters in this study, patients in the aripiprazole group reported lower means of intraoperative and postoperative HR and MAP. Furthermore, bradycardia and hypotension were reported more frequently in the aripiprazole group.…”

Section: Discussionmentioning

confidence: 60%

“…Some case series have reported that aripiprazole could be an effective medication in the treatment of migraine 16 and chronic pain disorders 17 . In contrast, Diep et al 45 found that aripiprazole may be ineffective in the reduction of pain severity among patients with comorbid pain and depression who received a combination of escitalopram, an antidepressant, and aripiprazole. They mentioned the likelihood of escitalopram and aripiprazole drug interaction.…”

Section: Discussionmentioning

confidence: 99%

“…They mentioned the likelihood of escitalopram and aripiprazole drug interaction. However, the previous study was a secondary analysis that lacked randomization or comparison to placebo 45 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Preoperative Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy

Alansary,

Elbeialy

2024

The Clinical Journal of Pain

View full text Add to dashboard Cite

Objectives: Aripiprazole is a second-generation atypical antipsychotic with worldwide clinical approval. Nevertheless, its perioperative antinociceptive application has not been studied. As a result, the purpose of this study was to investigate the analgesic effects of perioperative aripiprazole on reducing postoperative pain, as well as the possible adverse effects. Methods: This randomized controlled study enrolled eighty female patients scheduled for laparoscopic hysterectomy who were assigned randomly into two equal groups in 1:1; Aripiprazole group (n=40): patients received an aripiprazole 30 mg tablet orally three hours before surgery, and Placebo group (n=40): patients received a placebo tablet three hours before surgery. The 24-hour morphine consumption postoperatively was the primary outcome, and the time to the first analgesic request, sedation scores, and the incidence of perioperative adverse events were the secondary outcomes. Results: The mean 24-hour morphine consumption was significantly lower with aripiprazole (2.5±0.5 mg) than with placebo (23.7±1.6 mg) (Mean±SE −21.2±0.3, 95% CI: −21.7 to −20.6, P<0.001). In addition, mean time to the first analgesic request was significantly longer with aripiprazole (212.2±14.7 min) than with placebo (27.0±2.0 min) (Mean±SE 185.2±2.3, 95% CI: 180.5 to 189.8, P<0.001). Furthermore, aripiprazole group reported higher sedation scores (P<0.001). Bradycardia and hypotension were reported more frequently among patients in the aripiprazole group (P<0.05). Discussion: Aripiprazole was effective in reducing pain following laparoscopic hysterectomy. Although self-limited, side effects should be taken into consideration when using the medication perioperatively.

show abstract

Section: Discussionmentioning

confidence: 60%